Bristol Myers Squibb (BMY) Liabilities from Discontinued Operations (2013)
Bristol Myers Squibb (BMY) posted quarterly Liabilities from Discontinued Operations of 4931000000.0 for Q4 2013.
Bristol Myers Squibb (BMY) Liabilities from Discontinued Operations (2013) Analysis & Trends
Bristol Myers Squibb has disclosed Liabilities from Discontinued Operations across 1 years of filings, most recently posting 4931000000.0 for Q4 2013.
- In Q4 2013, Liabilities from Discontinued Operations changed N/A year-over-year to 4931000000.0; the TTM figure through Dec 2013 stood at 4931000000.0 (changed N/A YoY), while the FY2013 annual figure was 4931000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations steadied at 4931000000.0 in Q4 2013.
- Over the last five years, Liabilities from Discontinued Operations for BMY reached as high as 4931000000.0 in Q4 2013 and fell as low as 4931000000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 4.93 Bn |
| Dec 31, 2013 | 4.93 Bn |